Teva launches authorized generics: Actos, ACTOplus met

Teva Pharmaceutical Industries Ltd has launched authorized generics of products indicated for use with diet and exercise to improve blood glucose control in adults with type 2 diabetes.

Teva Pharmaceutical Industries Ltd has launched an authorized generic (AG) of Actos (pioglitazone hydrochloride tablets) in 15-mg, 30-mg, and 45-mg dose strengths, as well as an AG of ACTOplus met (pioglitazone/metformin tablets) in 15 mg/500 mg and 15 mg/850 mg dose strengths. Both products are indicated for use with diet and exercise to improve blood glucose control in adults with type 2 diabetes.

Actos and ACTOplus met are marketed by Takeda Pharmaceuticals U.S.A.

The brand product, Actos, had annual sales of approximately $2.7 billion in the United States, and the combination product, ACTOplus met, had annual sales totaling $413 million in the United States, according to IMS sales data as of June 30, 2012.